This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chiu, D. Articles by Grotta, J. C. Search for Related Content PubMed PubMed Citation Articles by Chiu, D. Articles by Grotta, J. C.

(Stroke. 1998;29:1347-1351.)
© 1998 American Heart Association, Inc.

Original Contributions

Clinical Features of Moyamoya Disease in the United States

David Chiu, MD; Peter Shedden, MSc, MD, FRCSC; Patti Bratina, RN; James C. Grotta, MD

From the Department of Neurology, Baylor College of Medicine (D.C.), The Greater Houston Neurosurgery Center (P.S.), and the Department of Neurology, University of Texas Houston Health Sciences Center (P.B., J.C.G.), Houston, Tex.

Correspondence to David Chiu, MD, Baylor College of Medicine, Department of Neurology, Suite 1801, 6550 Fannin, Houston, TX 77030. E-mail dchiu{at}bcm.tmc.edu

	Abstract

Top Abstract Introduction Subjects and Methods Results Discussion References

 
Background and Purpose—We report the clinical features and longitudinal outcome of the largest cohort of patients with moyamoya disease described from a single institution in the western hemisphere. Moyamoya disease in Asia usually presents with ischemic stroke in children and intracranial hemorrhage in adults.

Methods—Our study population included all patients with moyamoya disease evaluated at a university hospital in Houston, Texas from 1985 through 1995 (n=35). We used Kaplan-Meier methods to estimate individual and hemispheric stroke risk by treatment status (medical versus surgical). Predictors of neurological outcome were assessed.

Results—The ethnic background of our patients was representative of the general population in Texas. The mean age at diagnosis was 32 years (range, 6 to 59 years). Ischemic stroke or transient ischemic attack was the predominant initial symptom in both adults and children. Of the 6 patients with intracranial hemorrhage, 5 had an intraventricular site of hemorrhage. The crude stroke recurrence rate was 10.3% per year in 116 patient-years of follow-up. Twenty patients underwent surgical revascularization, the most common procedure being encephaloduroarteriosynangiosis. The 5-year risk of ipsilateral stroke after synangiosis was 15%, compared with 20% for medical treatment and 22% overall for surgery.

Conclusions—Our observations indicate that moyamoya disease may have a different clinical expression in the United States than in Asia, and may demonstrate a trend toward a lower stroke recurrence rate and better functional outcome after synangiosis.

Key Words: moyamoya disease • stroke, ischemic • intraventricular hemorrhage • epidemiology

	Introduction

Top Abstract Introduction Subjects and Methods Results Discussion References

 
Moyamoya disease is a chronic cerebral vasculopathy first described in 1957 by Takeuchi and Shimizu.¹ Progressive occlusion of the arteries of the circle of Willis leads to development of the characteristic collateral vessels after which the disease is named. Suzuki and Takaku² observed that the collateral vessels give the appearance of a puff of smoke on arteriography and anointed the name "moyamoya" in 1969.

Since that time, more than 3000 cases of moyamoya disease have been described in Japan.³ The disease occurs worldwide but is rare outside Asia.⁴ A total of 239 cases of moyamoya disease had been reported in the United States as of 1996.^{4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40} The genetic and/or environmental factors that contribute to the prevalence of moyamoya disease in Japan and other Pacific Rim countries are unknown.

In Japan, the onset of moyamoya disease has a bimodal age distribution. The first peak occurs in early childhood, and a second peak affects adults in the fourth decade of life.⁴¹ A predilection for ischemic cerebrovascular events in childhood and hemorrhagic strokes in adults has also been observed.⁴² Although no randomized clinical trials have been carried out, surgical revascularization is favored in children.^{43 44}

We set out to investigate whether differences exist between moyamoya disease in the United States and Japan with regard to demographic characteristics, clinical presentation, natural history, or response to surgical treatment. Our cohort of patients represents the largest group of patients followed longitudinally from a single institution in the western hemisphere.

	Subjects and Methods

Top Abstract Introduction Subjects and Methods Results Discussion References

 
We identified all patients with angiographically proved moyamoya disease evaluated at the University of Texas–Houston Health Sciences Center from 1985 through 1995. Subjects had unilateral or bilateral stenosis or occlusion of the distal internal carotid, proximal middle cerebral, and/or proximal anterior cerebral arteries associated with an abnormal network of fine collateral vessels at the base of the brain. Patients with "secondary" moyamoya disease due to identified etiologies such as atherosclerosis or sickle cell disease were excluded.

Demographic data, clinical history, medical therapy, and surgical interventions for the 35 patients identified with idiopathic moyamoya disease were recorded. Of these, 32 had definite moyamoya disease and 3 had probable moyamoya (unilateral involvement).⁴⁵ We were able to obtain clinic or telephone interview with 31 patients (89%), and assessed recurrent stroke symptoms, employment status, and neurological disability based on a modified Rankin scale.

Kaplan-Meier methods were used to estimate individual and hemispheric stroke risk stratified by treatment status (medical versus surgical). Cox regression analysis was performed to adjust for confounding clinical variables. Predictors of disability outcome were tested by Fisher's exact test and multiple logistic regression.

	Results

Top Abstract Introduction Subjects and Methods Results Discussion References

 
The ethnic distribution of our subjects reflects the population of our referral area (Figure 1). Only 2 patients were of Asian descent–1 Chinese and 1 Indian. The mean age at onset of symptoms was 32 years, ranging from 6 to 59 years (Figure 2). There were 7 patients under age 18 years, but a peak incidence in early childhood was not observed, in contrast to the experience in Japan.⁴¹ The female predominance (25 to 10) in our cohort has been noted in previous studies.

View larger version (16K): [in this window] [in a new window]   Figure 1. Pie chart shows ethnic background of study participants (n=35).

View larger version (9K): [in this window] [in a new window]   Figure 2. Graph shows age of study participants at onset of symptoms.

The initial symptom was a cerebral ischemic event in 26 patients and a hemorrhagic stroke in 6 patients (Table 1). The literature indicates a preponderance of hemorrhagic stroke in adult patients with moyamoya disease in Japan and South Korea,⁴² but this is at variance with our US experience. Of our adult patients, 23 presented with ischemic events compared with 3 patients with hemorrhagic strokes. Concurrent arteriographic findings were basilar tip aneurysms in 3 subjects, a posterior communicating artery aneurysm in 1 patient, and a parietal arteriovenous malformation in 1 individual.

View this table: [in this window] [in a new window]   Table 1. Presenting Symptoms of Study Participants

The mean period of follow-up after diagnosis of moyamoya disease was 40±31 (mean±SD) months. Ten ischemic strokes and 2 subarachnoid hemorrhages occurred in this period, for a crude stroke recurrence rate of 10.3% per year. No individual with an initial presentation of ischemic stroke or transient ischemic attack developed a hemorrhage, and no patient with an index hemorrhage subsequently suffered an ischemic stroke.

Twenty patients underwent surgical revascularization procedures, 11 of which were bilateral. Encephaloduroarteriosynangiosis (EDAS) was the most frequently performed operation, carried out in 24 of 31 hemispheres. EDAS is a nonanastomotic procedure in which a branch of the external carotid artery, usually the superficial temporal artery, is placed intradurally on the brain to allow development of collateral blood supply.^{46 47} Other surgeries performed were encephaloduroarteriomyosynangiosis (EDAMS), which involves transposing the temporalis muscle with the superficial temporal artery⁴⁸; direct extracranial-intracranial bypass⁴⁹; and omental transposition.³² Perioperative stroke occurred in 4 of 31 cases (13%): 1 of 24 EDAS, 0 of 2 EDAMS, 1 of 2 extracranial-intracranial bypasses, and 2 of 3 omental transpositions, of which one was fatal. The complication rate for the synangiosis operations (EDAS and EDAMS) was 4%.

The Kaplan-Meier estimate of recurrent stroke risk after diagnosis of moyamoya disease is 18% in the first year and roughly 5% per year thereafter, for a cumulative 5-year risk of 40% (Figure 3). The 5-year risk of ipsilateral stroke after surgical treatment was 22%, compared with 20% under medical treatment (Figure 4); however, a substantial proportion of the stroke risk in the surgical group is perioperative, and the data suggest that the late stroke risk may be reduced. The 5-year risk of ipsilateral stroke after EDAS or EDAMS was only 15%, owing largely to the low surgical complication rate of these procedures. There was no significant difference in stroke incidence in the surgical and medical groups, which remained true after adjusting for age, sex, race, hypertension, initial clinical presentation (infarct, hemorrhage, or other), and number of strokes prior to diagnosis.

View larger version (7K): [in this window] [in a new window]   Figure 3. Kaplan-Meier estimate of recurrent stroke risk.

View larger version (11K): [in this window] [in a new window]   Figure 4. Kaplan-Meier estimate of recurrent stroke risk per hemisphere by surgical status.

Follow-up information on disability and functional status was available in 31 of 35 patients (89%). Four patients (13%) died, 3 from recurrent strokes (1 perioperative) and 1 from metastatic cancer. Eighteen (58%) had no disability (modified Rankin scale of 0 or 1) and 9 (29%) had mild or moderate disability but were able to walk (modified Rankin scale of 2 or 3). No surviving subject was severely disabled or unable to walk (modified Rankin scale of 4 or 5). Fifteen (48%) were employed or regular full-time students. The functional outcome of patients was not significantly related to age, sex, race, hypertension, initial clinical presentation (infarct, hemorrhage, or other), or number of strokes prior to diagnosis. There was a trend for better outcome in favor of patients undergoing EDAS or EDAMS but not surgery overall (Table 2).

View this table: [in this window] [in a new window]   Table 2. Characteristics and Functional Outcome of Surgical vs Medical Patients

	Discussion

Top Abstract Introduction Subjects and Methods Results Discussion References

 
Moyamoya disease has been described on every continent and in all ethnic groups, but remains rare outside Japan and other countries of the Far East. The etiology of the disorder is obscure,^{50 51} and the reason for the large number of cases observed at our institution relative to other centers in the United States is also unclear. Since the diagnosis of moyamoya disease is based on its angiographic features, case detection hinges on the performance of angiography. Although angiography is part of the standard diagnostic workup of subarachnoid hemorrhage, the use of angiography in the evaluation of ischemic stroke varies widely in practice. Moyamoya disease is thus particularly underrecognized as a cause of ischemic stroke.

Several differences between moyamoya disease in the United States and Japan are notable. First, we observed a predominance of ischemic rather than hemorrhagic stroke in adult cases. Only 13% of our adult patients had intracranial hemorrhages (17% overall). A recent US multicenter study by Numaguchi et al⁵² revealed a similarly low prevalence of intracranial hemorrhage (14%). In Hawaii, the proportion of moyamoya patients with intracranial hemorrhage is higher (29%), but the majority are of Asian ethnicity.⁵³ Second, an age peak in childhood was absent in our study. Numaguchi et al⁵² found a high incidence in the first decade of life, but 2 of the contributing institutions were children's hospitals. We recognize the possibility of referral bias at our center as well. The best way to minimize referral bias is through a population-based survey. In such a study in Hawaii, only 4 of 21 patients were under 18 years of age,⁵³ a percentage very similar to that in our study. Moyamoya disease may be a heterogeneous syndrome rather than a single disease. Moyamoya-like vascular changes are associated with conditions as diverse as sickle cell disease, neurofibromatosis, Down's syndrome, and cranial irradiation.^{4 54} Whether a different form of moyamoya disease is prevalent in the United States or its expression altered by genetic or environmental cofactors is unknown.

Aneurysms and arteriovenous malformations, detected in 11% of our cases, have a recognized association with moyamoya disease.^{9 55} We observed aneurysms at locations of increased flow: the basilar tip and posterior communicating artery. Moyamoya disease causes shunting of flow from the vertebrobasilar circulation to the carotid territory. We found a predilection for an intraventricular location of hemorrhage. Five of our 6 patients with intracranial hemorrhage had an intraventricular site. Moyamoya disease should be suspected in such patients.⁵⁶

The surgical treatment performed most frequently at our institution and associated with the lowest complication rate (4%) was EDAS. EDAS has been the favored procedure at our center since 1993. Surgical management includes strict maintenance of normotension, euvolemia, and normocapnia and the use of nimodipine perioperatively. Individuals with spontaneous transdural collateral vessels were not considered for synangiosis. Patients undergoing bilateral procedures were given a hiatus of several weeks between operations. Medical interventions included antiplatelet agents (aspirin and ticlopidine), rheologic therapy (pentoxifylline), and calcium channel antagonists (nimodipine and nicardipine),¹⁷ although the efficacy of these treatments has not been proven. We avoided the long-term use of anticoagulation because of the concern for hemorrhagic stroke.

Improvement of cerebral blood flow and even resolution of moyamoya vessels following surgical treatment for moyamoya disease have been demonstrated in previous studies, but long-term data on clinical end points are scarce and the risk of recurrent stroke heretofore undefined.^{54 57 58 59 60 61} We found that the stroke recurrence risk was highest in the first year after diagnosis (18%) and that it decreased to 5% per year thereafter into the fifth year. The 5-year stroke recurrence risk is similar for medical and surgical treatment overall, although the data suggest that stroke incidence may be reduced by surgery after the first year. EDAS and EDAMS were associated with a lower complication rate and a lower 5-year stroke risk. We were unable to detect a difference in functional outcome between medical and surgical patients overall, but once again there was a trend favoring patients undergoing EDAS or EDAMS (Table 2). The tendency for patients with high-grade disease to be treated surgically creates a bias that could obscure a benefit of surgery, but statistical adjustment for the number of strokes prior to diagnosis and the type of clinical presentation did not alter our findings. Further refinements in anesthesia, surgical technique, and perioperative care should lower surgical morbidity⁶² and enhance the potential benefit of revascularization.

The role of surgical treatment in moyamoya disease needs further evaluation with a focus on long-term clinical outcome and stroke recurrence. Is the response similar in adults and children? Does surgery reduce the risk of both hemorrhagic and ischemic stroke?⁶³ Is there a plateau phase after which the disease may be considered quiescent or "burned out?" A randomized clinical trial is warranted and will likely be feasible only in Japan. At the same time, investigations into the mechanisms of disease are planned that will explore differences between Asian and US moyamoya patients. The answers to these questions will gain importance as moyamoya disease is increasingly recognized in young patients with stroke.

Received February 24, 1998; revision received March 26, 1998; accepted April 16, 1998.

	References

Top Abstract Introduction Subjects and Methods Results Discussion References

 
1. Takeuchi K, Shimizu K. Hypogenesis of bilateral internal carotid arteries. No To Shinkei. 1957;9:37–43.

2. Suzuki J, Takaku A. Cerebrovascular `moyamoya' disease: disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20:288–299.[Abstract/Free Full Text]

3. Yanagawa H. Annual Report by Research Committee on Epidemiology of Intractable Disease, Ministry of Health and Welfare, Japan, 1991.

4. Yonekawa Y, Goto Y, Ogata N. Moyamoya disease: diagnosis, treatment, and recent achievement. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. Stroke: Pathophysiology, Diagnosis, and Management. 2nd ed. New York, NY: Churchill Livingstone; 1992:721–747.

5. Miller JH, Khonsary A, Raffel C. The scintigraphic appearance of childhood moyamoya disease on cerebral perfusion imaging. Pediatr Radiol. 1996;26:833–838.[Medline] [Order article via Infotrieve]

6. Cramer SC, Robertson RL, Dooling EC, Scott RM. Moyamoya and Down syndrome: clinical and radiological features. Stroke. 1996;27:2131–2135.[Abstract/Free Full Text]

7. Barrall JL, Summers CG. Ocular ischemic syndrome in a child with moyamoya disease and neurofibromatosis. Surv Ophthalmol. 1996;40:500–504.[Medline] [Order article via Infotrieve]

8. Abboud MR, Jackson SM, Barredo J, Holden KR, Cure J, Laver J. Neurologic complications following bone marrow transplantation for sickle cell disease. Bone Marrow Transplant. 1996;17:405–407.[Medline] [Order article via Infotrieve]

9. Schmit BP, Burrows PE, Kuban K, Goumnerova L, Scott RM. Acquired cerebral arteriovenous malformation in a child with moyamoya disease: case report. J Neurosurg. 1996;84:677–680.[Medline] [Order article via Infotrieve]

10. Halpern EJ, Nack TL. Prospective diagnosis of moyamoya disease with Doppler ultrasonography. J Ultrasound Med. 1995;14:157–160.[Medline] [Order article via Infotrieve]

11. Horowitz M, Yonas H, Albright AL. Evaluation of cerebral blood flow and hemodynamic reserve in symptomatic moyamoya disease using stable Xenon-CT blood flow. Surg Neurol. 1995;44:251–262.[Medline] [Order article via Infotrieve]

12. Park M, Raila FA, Russell WF. Moyamoya disease in an adult with Down syndrome: comparison of magnetic resonance angiography and conventional angiography. South Med J. 1996;89:89–92.[Medline] [Order article via Infotrieve]

13. Adelson PD, Scott RM. Pial synangiosis for moyamoya syndrome in children. Pediatr Neurosurg. 1995;23:26–33.[Medline] [Order article via Infotrieve]

14. Pavlakis SG, Verlander PC, Gould RJ, Strimling BC, Auerbach AD. Fanconi anemia and moyamoya: evidence for an association. Neurology. 1995;45:998–1000.[Abstract/Free Full Text]

15. Shoskes DA, Novick AC. Surgical treatment of renovascular hypertension in moyamoya disease: case report and review of the literature. J Urol. 1995;153:450–452.[Medline] [Order article via Infotrieve]

16. Vanefsky MA, Steinberg GK. Current surgical management of moya-moya disease. Stroke. 1995;26:172. Abstract.

17. Hosain SA, Hughes JT, Forem SL, Wisoff J, Fish I. Use of a calcium channel blocker (nicardipine HCl) in the treatment of childhood moyamoya disease. J Child Neurol. 1994;9:378–380.[Abstract/Free Full Text]

18. Massoud TF, Guglielmi G, Vinuela F, Duckwiler GR. Saccular aneurysms in moyamoya disease: endovascular treatment using electrically detachable coils. Surg Neurol. 1994;41:462–467.[Medline] [Order article via Infotrieve]

19. Ueki K, Meyer FB, Mellinger JF. Moyamoya disease: the disorder and surgical treatment. Mayo Clin Proc. 1994;69:749–757.[Medline] [Order article via Infotrieve]

20. Sharma SK, Wallace DH, Gajraj NM, Willis C, Sidawi E. Epidural anesthesia for a patient with moyamoya disease presenting for cesarean section. Anesth Analg. 1994;79:183–185.[Abstract/Free Full Text]

21. Hopper KD. Neuroradiology case of the day: moyamoya disease. AJR Am J Roentgenol. 1994;162:1479–1480.[Medline] [Order article via Infotrieve]

22. Maas K, Barkovich AJ, Dong L, Edwards MS, Piecuch RE, Charlton V. Selected indications for and applications of magnetic resonance angiography in children. Pediatr Neurosurg. 1994;20:113–125.[Medline] [Order article via Infotrieve]

23. Muppala M, Castaldo JE. Unilateral supraclinoid internal carotid artery stenosis with moyamoya-like vasculopathy. J Neuroimaging. 1994;4:11–16.[Medline] [Order article via Infotrieve]

24. Petty LA. Anesthetic management of a patient with moyamoya disease: a case report. AANA Journal. 1993;61:277–281.[Medline] [Order article via Infotrieve]

25. Amin-Hanjani S, Kuhn M, Sloane N, Chatwani A. Moyamoya disease in pregnancy: a case report. Am J Obstet Gynecol. 1993;169:395–396.[Medline] [Order article via Infotrieve]

26. Bernstein AL. Hemiplegic migraine and moyamoya disease. American J Dis Child. 1993;147:718–719. Letter.

27. Drew JM, Scott JA, Chua GT. General case of the day: moyamoya syndrome in a child with sickle cell disease. Radiographics. 1993;13:483–484.[Medline] [Order article via Infotrieve]

28. Asfora WT, West M, McClarty B. Angiography of encephalomyosynangiosis and superficial temporal artery to middle cerebral artery anastomosis in moyamoya disease. AJNR Am J Neuroradiol. 1993;14:29–30.[Abstract]

29. Feole JB, Ali A, Fordham EW, Huckman M, Shenker DM. Serial SPECT imaging in moyamoya using I-123 IMP. A method of noninvasive evaluation and follow-up. Clin Nucl Med. 1993;18:43–45.[Medline] [Order article via Infotrieve]

30. Woody RC, Perrot LJ, Beck SA. Neurofibromatosis cerebral vasculopathy in an infant: clinical, neuroradiographic, and neuropathologic studies. Pediatr Pathol. 1992;12:613–619.[Medline] [Order article via Infotrieve]

31. Steinke W, Tatemichi TK, Mohr JP, Massaro A, Prohovnik I, Solomon RA. Caudate hemorrhage with moyamoya-like vasculopathy from atherosclerotic disease. Stroke. 1992;23:1360–1363.[Abstract/Free Full Text]

32. Havlik RJ, Fried I, Chyatte D, Modlin IM. Encephalo-omental synangiosis in the management of moyamoya disease. Surgery. 1992;111:156–162.[Medline] [Order article via Infotrieve]

33. Oppenheim JS, Gennuso R, Sacher M, Hollis P. Acute atraumatic subdural hematoma associated with moyamoya disease in an African-American. Neurosurgery. 1991;28:616–618.[Medline] [Order article via Infotrieve]

34. Pavlakis SG, Schneider S, Black K, Gould RJ. Steroid-responsive chorea in moyamoya disease. Mov Disord. 1991;6:347–349.[Medline] [Order article via Infotrieve]

35. Levine SR, Fagan SC, Pessin MS, Silbergleit R, Floberg J, Selwa JF, Vogel CM, Welch KM. Accelerated intracranial occlusive disease, oral contraceptives, and cigarette use. Neurology. 1991;41:1893–1901.[Abstract/Free Full Text]

36. Martino JD, Werner LO. Hypocarbia during anaesthesia in children with moyamoya disease. Can J Anaesth. 1991;38:942–943. Letter.[Medline] [Order article via Infotrieve]

37. Hardy RE, Obianyo I, Shu HS, Adair L. Unilateral moyamoya disease, intracranial aneurysm, and a pituitary adenoma: a case report. J Natl Med Assoc. 1991;83:827–830.[Medline] [Order article via Infotrieve]

38. Shin IS, Cheng R, Pordell GR. Striking CT scan findings in a case of unilateral moyamoya disease—a case report. Angiology. 1991;42:665–641.

39. Rooney CM, Kaye EM, Scott RM, Klucznik RP, Rosman NP. Modified encephaloduroarteriosyangiosis as a surgical treatment of childhood moyamoya disease: report of five cases. J Child Neurol. 1991;6:24–31.[Abstract/Free Full Text]

40. Nieto R, Rosenbaum D, Fletcher S, Ehni B, Kopanicky D, Yeakley J, Yatsu F, Grotta J. Treatment of adult moyamoya disease by encephalo-duro-artero-synangiosis: five case reports. J Stroke Cerebrovasc Dis. 1991;1:71–75.

41. Suzuki J, Kodama N. Moyamoya disease: a review. Stroke. 1983;14:104–109.[Abstract/Free Full Text]

42. Ikezaki K, Han DH, Kawano T, Kinukawa N, Fukui M. A clinical comparison of definite moyamoya disease between South Korea and Japan. Stroke. 1997;28:2513–2517.[Abstract/Free Full Text]

43. Yamada I, Matsushima Y, Suzuki S. Childhood moyamoya disease before and after encephalo-duro-arterio-synangiosis: an angiographic study. Neuroradiology. 1992;34:318–322.[Medline] [Order article via Infotrieve]

44. Ross IB, Shevell MI, Montes JL, Rosenblatt B, Watters GV, Farmer JP, O'Gorman AM. Encephaloduroarteriosynangiosis (EDAS) for the treatment of childhood moyamoya disease. Pediatr Neurol. 1994;10:199–204.[Medline] [Order article via Infotrieve]

45. The Research Committee of Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Guidelines for diagnosis. Clin Neurol Neurosurg. 1997;99(suppl 2):S238–S240.

46. Fukushima T. Surgical aspects of moyamoya disease. In: Welch KMA, Caplan LR, Reis DJ, Siesjö BK, Weir B, eds. Primer on Cerebrovascular Diseases. San Diego, Calif: Academic Press; 1997:586–589.

47. Kashiwagi S, Kato S, Yasuhara S, Wakuta Y, Yamashita T, Ito H. Use of a split dura for revascularization of ischemic hemispheres in moyamoya disease. J Neurosurg. 1996;85:380–383.[Medline] [Order article via Infotrieve]

48. Kinugasa K, Mandai S, Kamata I, Sugiu K, Ohmoto T. Surgical treatment of moyamoya disease: operative technique for encephalo-duro-arterio-myo-synangiosis, its follow-up, clinical results, and angiograms. Neurosurgery. 1993;32:527–531.[Medline] [Order article via Infotrieve]

49. Suzuki Y, Negoro M, Shibuya M, Yoshida J, Negoro T, Watanabe K. Surgical treatment for pediatric moyamoya disease: use of the superficial temporal artery for both areas supplied by the anterior and middle cerebral arteries. Neurosurgery. 1997;40:324–330.[Medline] [Order article via Infotrieve]

50. Yoshimoto T, Houkin K, Takahashi A, Abe H. Angiogenic factors in moyamoya disease. Stroke. 1996;27:2160–2165.[Abstract/Free Full Text]

51. Houkin K, Abe H, Yoshimoto T, Takahashi A. Is `unilateral' moyamoya disease different from moyamoya disease? J Neurosurg.. 1996;85:772–776.[Medline] [Order article via Infotrieve]

52. Numaguchi Y, Gonzalez CF, Davis PC, Monajati A, Afshani E, Chang J, Sutton CL, Lee RR, Shibata DK. Moyamoya disease in the United States. Clin Neurol Neurosurg. 1997;99(suppl 2):S26–S30.

53. Graham JF, Matoba A. A survey of moyamoya disease in Hawaii. Clin Neurol Neurosurg. 1997;99(suppl 2):S31–S35.

54. Garg BP, Bruno A, Biller J. Moyamoya disease and cerebral ischemia. In: Batjer HH, ed. Cerebrovascular Disease. Philadelphia, Pa: Lippincott-Raven; 1997:489–499.

55. Kawaguchi S, Sasaki T, Morimoto T, Kakizaki T, Kamada K. Characteristics of intracranial aneurysms associated with moyamoya disease: a review of 111 cases. Acta Neurochir (Wien). 1996;138:1287–1294.[Medline] [Order article via Infotrieve]

56. Kawaguchi S, Sasaki T, Kakizaki T, Kamada K, Shimomura T, Iwanaga H. Clinical features of the haemorrhage type moyamoya disease based on 31 cases. Acta Neurochir (Wien). 1996;138:1200–1210.[Medline] [Order article via Infotrieve]

57. Maki Y, Nakada Y, Nose T, Yoshii Y. Clinical and radioisotopic follow-up study of `moyamoya.' Child's Brain. 1976;2:257–271.[Medline] [Order article via Infotrieve]

58. Ishii R, Takeuchi S, Ibayashi K, Tanaka R. Intelligence in children with moyamoya disease: evaluation after surgical treatments with special reference to changes in cerebral blood flow. Stroke. 1984;15:873–877.[Abstract/Free Full Text]

59. Wang MY, Steinberg GK. Rapid and near-complete resolution of moyamoya vessels in a patient with moyamoya disease treated with superficial temporal artery–middle cerebral artery bypass. Pediatr Neurosurg. 1996;24:145–150.[Medline] [Order article via Infotrieve]

60. Ishikawa T, Houkin K, Kamiyama H, Abe H. Effects of surgical revascularization on outcome of patients with pediatric moyamoya disease. Stroke. 1997;28:1170–1173.[Abstract/Free Full Text]

61. Nakashima H, Meguro T, Kawada S, Hirotsune N, Ohmoto T. Long-term results of surgically treated moyamoya disease. Clin Neurol Neurosurg. 1997;99(suppl 2):S156–S161.

62. Matsushima Y, Aoyagi M, Suzuki R, Tabata H, Ohno K. Perioperative complications of encephalo-duro-arterio-synangiosis: prevention and treatment. Surg Neurol. 1991;36:343–353.[Medline] [Order article via Infotrieve]

63. Houkin K, Kamiyama, Abe H, Takahashi A, Kuroda S. Surgical therapy for adult moyamoya disease: can surgical revascularization prevent the recurrence of intracerebral hemorrhage? Stroke.. 1996;27:1342–1346.[Abstract/Free Full Text]

This article has been cited by other articles:

				J-M Kim, S-H Lee, and J-K Roh Changing ischaemic lesion patterns in adult moyamoya disease J. Neurol. Neurosurg. Psychiatry, January 1, 2009; 80(1): 36 - 40. [Abstract] [Full Text] [PDF]

				M. Kraemer, W. Heienbrok, and P. Berlit Moyamoya Disease in Europeans Stroke, December 1, 2008; 39(12): 3193 - 3200. [Abstract] [Full Text] [PDF]

				S. Kuriyama, Y. Kusaka, M. Fujimura, K. Wakai, A. Tamakoshi, S. Hashimoto, I. Tsuji, Y. Inaba, and T. Yoshimoto Prevalence and Clinicoepidemiological Features of Moyamoya Disease in Japan: Findings From a Nationwide Epidemiological Survey Stroke, January 1, 2008; 39(1): 42 - 47. [Abstract] [Full Text] [PDF]

				V. Ganesan, M. Prengler, A. Wade, and F. J. Kirkham Clinical and Radiological Recurrence After Childhood Arterial Ischemic Stroke Circulation, November 14, 2006; 114(20): 2170 - 2177. [Abstract] [Full Text] [PDF]

				K. W. Neff, P. Horn, P. Schmiedek, C. Duber, and D. J. Dinter 2D cine phase-contrast MRI for volume flow evaluation of the brain-supplying circulation in moyamoya disease. Am. J. Roentgenol., July 1, 2006; 187(1): W107 - W115. [Abstract] [Full Text] [PDF]

				C. L. Hallemeier, K. M. Rich, R. L. Grubb Jr, M. R. Chicoine, C. J. Moran, D. T. Cross III, G. J. Zipfel, R. G. Dacey Jr, and C. P. Derdeyn Clinical Features and Outcome in North American Adults With Moyamoya Phenomenon Stroke, June 1, 2006; 37(6): 1490 - 1496. [Abstract] [Full Text] [PDF]

				Y. Fushimi, Y. Miki, K.-i. Kikuta, T. Okada, M. Kanagaki, A. Yamamoto, K. Nozaki, N. Hashimoto, T. Hanakawa, H. Fukuyama, et al. Comparison of 3.0- and 1.5-T Three-dimensional Time-of-Flight MR Angiography in Moyamoya Disease: Preliminary Experience Radiology, April 1, 2006; 239(1): 232 - 237. [Abstract] [Full Text] [PDF]

				A.L. Jefferson, G. Glosser, J.A. Detre, G. Sinson, and D.S. Liebeskind Neuropsychological and Perfusion MR Imaging Correlates of Revascularization in a Case of Moyamoya Syndrome AJNR Am. J. Neuroradiol., January 1, 2006; 27(1): 98 - 100. [Abstract] [Full Text] [PDF]

				M. F. Rafay, A. Al-Futaisi, S. Weiss, and D. Armstrong Hypomelanosis of Ito and Moyamoya Disease J Child Neurol, November 1, 2005; 20(11): 924 - 926. [Abstract] [PDF]

				K. Aydin, C. Okuyaz, K. Gucuyener, A. Serdaroglu, and S. Akpek Moyamoya Disease Presented With Migrainelike Headache in a 4-Year-Old Girl J Child Neurol, May 1, 2003; 18(5): 361 - 363. [Abstract] [PDF]

				E. Y. Yilmaz, M. B. Pritz, A. Bruno, A. Lopez-Yunez, and J. Biller Moyamoya: Indiana University Medical Center Experience Arch Neurol, August 1, 2001; 58(8): 1274 - 1278. [Abstract] [Full Text] [PDF]

				M. Bonduel, M. Hepner, G. Sciuccati, A. F. Torres, S. Tenembaum, and G. de Veber Prothrombotic Disorders in Children With Moyamoya Syndrome Editorial Comment Stroke, August 1, 2001; 32(8): 1786 - 1792. [Abstract] [Full Text] [PDF]

				A. Serdaroglu, F. Simsek, K. Gucuyener, A. Oguz, C. Karadeniz, and M. Balibey Moyamoya Syndrome After Radiation Therapy for Optic Pathway Glioma: Case Report J Child Neurol, November 1, 2000; 15(11): 765 - 767. [Abstract] [PDF]

				A. I. Dai, Z. A. Shaikh, and M. E. Cohen Early-Onset Moyamoya Syndrome in a Patient With Down Syndrome: Case Report and Review of the Literature J Child Neurol, October 1, 2000; 15(10): 696 - 699. [Abstract] [PDF]

				G. W. Albers, R. G. Hart, H. L. Lutsep, D. W. Newell, and R. L. Sacco Supplement to the Guidelines for the Management of Transient Ischemic Attacks : A Statement From the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association Stroke, November 1, 1999; 30(11): 2502 - 2511. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chiu, D. Articles by Grotta, J. C. Search for Related Content PubMed PubMed Citation Articles by Chiu, D. Articles by Grotta, J. C.